Patent: 9,114,179

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,114,179

Title:	Immunoconjugate formulations
Abstract:	The present invention provides an immunoconjugate formulation that is substantially free of particles, the immunoconjugate formulation comprising: an immunoconjugate and one or more excipients selected from the group consisting of: sucrose, polysorbate 20, polysorbate 80, cyclodextrin, dextrose, glycerol, polyethylene glycol, mannitol, sodium chloride, and an amino acid, wherein the formulation is a buffered aqueous solution having a pH of 4.5 to 7.6. The present invention also provides an immunoconjugate formulation that is substantially free of aggregates, the immunoconjugate formulation comprising: an immunoconjugate and one or more excipients selected from the group consisting of histidine, sucrose, glycine and sodium chloride, wherein the formulation is a buffered aqueous solution having a pH of 4.5 to 7.6. The present invention further provides an immunoconjugate formulation that is substantially free of both particles and aggregates.
Inventor(s):	Zhang; Wei (Philadelphia, PA), Fleming; Michael S. (Londonderry, NH), Amphlett; Godfrey (Cambridge, MA), Chih; Hung-wei (Burlingame, CA), Bartlett; Elizabeth (Cambridge, MA)
Assignee:	ImmunoGen, Inc. (Waltham, MA)
Application Number:	11/498,139
Patent Claims:	see list of patent claims

Details for Patent 9,114,179

Glossary

Subscribe to access the full database, or Try it Free
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997	See Plans and Pricing	2025-08-03
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002	See Plans and Pricing	2025-08-03
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998	See Plans and Pricing	2025-08-03
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017	See Plans and Pricing	2025-08-03
Genentech, Inc.	RITUXAN HYCELA	rituximab and hyaluronidase human	Injection	761064	06/22/2017	See Plans and Pricing	2025-08-03
Genentech, Inc.	HERCEPTIN HYLECTA	trastuzumab and hyaluronidase-oysk	Injection	761106	02/28/2019	See Plans and Pricing	2025-08-03
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.